DK175666B1 - Behandling af autoimmune sygdomme ved oral administration af autoantigener - Google Patents
Behandling af autoimmune sygdomme ved oral administration af autoantigener Download PDFInfo
- Publication number
- DK175666B1 DK175666B1 DK198906516A DK651689A DK175666B1 DK 175666 B1 DK175666 B1 DK 175666B1 DK 198906516 A DK198906516 A DK 198906516A DK 651689 A DK651689 A DK 651689A DK 175666 B1 DK175666 B1 DK 175666B1
- Authority
- DK
- Denmark
- Prior art keywords
- mbp
- rats
- cell
- eae
- suppression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Marine Sciences & Fisheries (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rehabilitation Therapy (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6573487A | 1987-06-24 | 1987-06-24 | |
US6573487 | 1987-06-24 | ||
US8802139 | 1988-06-24 | ||
PCT/US1988/002139 WO1988010120A1 (fr) | 1987-06-24 | 1988-06-24 | Traitement de maladies auto-immunitaires par administration orale d'auto-antigenes |
Publications (3)
Publication Number | Publication Date |
---|---|
DK651689D0 DK651689D0 (da) | 1989-12-20 |
DK651689A DK651689A (da) | 1990-02-26 |
DK175666B1 true DK175666B1 (da) | 2005-01-10 |
Family
ID=22064733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK198906516A DK175666B1 (da) | 1987-06-24 | 1989-12-20 | Behandling af autoimmune sygdomme ved oral administration af autoantigener |
Country Status (8)
Country | Link |
---|---|
EP (2) | EP0359783B2 (fr) |
JP (1) | JP2512796B2 (fr) |
AT (2) | ATE258065T1 (fr) |
AU (1) | AU632991B2 (fr) |
CA (1) | CA1336954C (fr) |
DE (2) | DE3854741T3 (fr) |
DK (1) | DK175666B1 (fr) |
WO (1) | WO1988010120A1 (fr) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6645504B1 (en) | 1987-06-24 | 2003-11-11 | Autoimmune Inc. | Bystander suppression of type I diabetes by oral administration of glucagon |
US5645820A (en) * | 1987-06-24 | 1997-07-08 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
US5869054A (en) * | 1987-06-24 | 1999-02-09 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of autoantigens |
US5571499A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
US5641474A (en) * | 1987-06-24 | 1997-06-24 | Autoimmune, Inc. | Prevention of autoimmune diseases by aerosol administration of autoantigens |
US5571500A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
US5843445A (en) * | 1987-06-24 | 1998-12-01 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
US5849298A (en) * | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
CA1340012C (fr) * | 1987-08-17 | 1998-08-25 | Trustees Of Leland Stanford Jr. University | Determinant peptidique associe a l'immunite |
KR960002183B1 (ko) * | 1988-11-03 | 1996-02-13 | 쉐링 코포레이션 | 호산구증다증 억제또는 경감을 위한 약제학적 조성물 |
NO306996B1 (no) * | 1989-02-17 | 2000-01-24 | Bayer Ag | Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk |
IL89431A0 (en) * | 1989-02-27 | 1989-09-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of autoimmune diseases |
ATE158950T1 (de) * | 1989-07-14 | 1997-10-15 | Autoimmune Inc | Behandlung der autoimmunen uveoretinitis in menschen |
BR9007950A (pt) * | 1989-12-20 | 1992-10-27 | Brigham & Womens Hospital | Metodo para tratamento ou prevencao da manifestacao de uma doenca auto-imune em um mamifero,formulacao farmaceutica,metodo para tratamento de uma doenca auto-imune,e metodo para tratamento de um mamifero acometido de doenca auto-imune |
US5620686A (en) * | 1990-09-28 | 1997-04-15 | British Technology Group Limited | Antigen-antibody conjugates |
DE69123256T2 (de) * | 1990-09-28 | 1997-06-12 | British Tech Group | Antigen-antikörperkonjugaten |
IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
WO1992006708A1 (fr) * | 1990-10-15 | 1992-04-30 | Brigham And Women's Hospital | Traitement de maladies auto-immunes par administration orale d'auto-antigenes |
GB2251186A (en) * | 1990-12-04 | 1992-07-01 | Randall Neal Gatz | Polypeptide for use in treatment of autoimmune disease |
US6252040B1 (en) | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
US5817629A (en) | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
CA2164326A1 (fr) * | 1993-06-02 | 1994-12-08 | Wayne Robert Thomas | Peptides caches, utiles pour induire la tolerance immunitaire |
GB9319429D0 (en) | 1993-09-21 | 1993-11-03 | London Health Ass | Methods and products for controlling immune responses in mammals |
SI9520118A (sl) * | 1994-10-25 | 1998-08-31 | Immulogic Pharmaceutical Corporation | Sestavki in zdravljenje multiple skleroze |
US6379670B1 (en) | 1994-11-18 | 2002-04-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6251396B1 (en) | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6488933B2 (en) | 1995-07-05 | 2002-12-03 | Yeda Research And Development Co. Ltd. | Preparations for the treatment of T cell mediated diseases |
US5856446A (en) * | 1995-07-07 | 1999-01-05 | Autoimmune Inc. | Method of treating rheumatoid arthritis with low dose type II collagen |
US5843462A (en) | 1995-11-30 | 1998-12-01 | Regents Of The University Of Minnesota | Diphtheria toxin epitopes |
DE69739275D1 (de) * | 1996-01-05 | 2009-04-09 | Autoimmune Inc | Methode zur herstellung von type-ii kollagen |
BR9807112A (pt) * | 1997-01-24 | 2001-09-18 | Autoimmune Inc | Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato |
US7097845B2 (en) | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
CA2315537A1 (fr) | 1997-12-16 | 1999-06-24 | Regents Of The University Of Minnesota | Procedes permettant de traiter des reponses immunitaires indesirables |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
WO2000005250A1 (fr) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Traitement de maladies auto-immunes a l'aide du copolymere 1 et des copolymeres et peptides apparentes |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
AU2001249214A1 (en) | 2000-03-15 | 2001-09-24 | The Brigham And Women's Hospital, Inc. | Suppression of vascular disorders by mucosal administration of heat shock protein peptides |
US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
WO2002076503A1 (fr) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Traitement de maladies du systeme nerveux central au moyen d'anticorps diriges contre l'acetate de glatiramere |
HU229377B1 (hu) | 2000-08-21 | 2013-11-28 | Apitope Technology Bristol Ltd | Tolerogén humán peptidek |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US7429374B2 (en) | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
EP1641488B1 (fr) | 2003-06-23 | 2011-03-30 | Biotech Tools S.A. | Composition d'epitope pour administration par voie enterale, obtenue par hydrolyse de structures antigeniques a l'aide de chymotrypsine |
CA2590337C (fr) | 2004-12-15 | 2017-07-11 | Neuralab Limited | Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3989819A (en) * | 1969-03-05 | 1976-11-02 | American Cyanamid Company | Process for separating proteins from central nervous system tissue and treating experimentally induced demyelinating diseases |
US4350682A (en) † | 1979-05-11 | 1982-09-21 | Lescarden Ltd. | Cartilage extraction processes and products |
JP2633881B2 (ja) † | 1986-06-30 | 1997-07-23 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫調節組成物及びそれらの使用 |
CA1340012C (fr) † | 1987-08-17 | 1998-08-25 | Trustees Of Leland Stanford Jr. University | Determinant peptidique associe a l'immunite |
GB8803881D0 (en) * | 1988-02-19 | 1988-03-23 | Traqson Ltd | Novel photoactive compounds processes for their production & intermediates thereof |
AU3320089A (en) * | 1988-04-20 | 1989-10-26 | Hartech (Australia) Pty. Ltd. | Portable traffic lights |
-
1988
- 1988-06-24 DE DE3854741T patent/DE3854741T3/de not_active Expired - Lifetime
- 1988-06-24 DE DE3856566T patent/DE3856566T2/de not_active Expired - Lifetime
- 1988-06-24 EP EP88906457A patent/EP0359783B2/fr not_active Expired - Lifetime
- 1988-06-24 EP EP95102528A patent/EP0666080B1/fr not_active Expired - Lifetime
- 1988-06-24 AT AT95102528T patent/ATE258065T1/de not_active IP Right Cessation
- 1988-06-24 AU AU20797/88A patent/AU632991B2/en not_active Expired
- 1988-06-24 JP JP63506040A patent/JP2512796B2/ja not_active Expired - Lifetime
- 1988-06-24 CA CA000570406A patent/CA1336954C/fr not_active Expired - Fee Related
- 1988-06-24 AT AT88906457T patent/ATE130762T1/de not_active IP Right Cessation
- 1988-06-24 WO PCT/US1988/002139 patent/WO1988010120A1/fr active IP Right Grant
-
1989
- 1989-12-20 DK DK198906516A patent/DK175666B1/da not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE3856566T2 (de) | 2004-06-24 |
ATE258065T1 (de) | 2004-02-15 |
DE3856566D1 (de) | 2004-02-26 |
DE3854741T3 (de) | 2002-08-14 |
WO1988010120A1 (fr) | 1988-12-29 |
EP0359783B1 (fr) | 1995-11-29 |
DE3854741D1 (de) | 1996-01-11 |
AU632991B2 (en) | 1993-01-21 |
AU2079788A (en) | 1989-01-19 |
EP0359783A4 (fr) | 1990-06-27 |
EP0666080B1 (fr) | 2004-01-21 |
ATE130762T1 (de) | 1995-12-15 |
DK651689D0 (da) | 1989-12-20 |
CA1336954C (fr) | 1995-09-12 |
DE3854741T2 (de) | 1996-04-18 |
DK651689A (da) | 1990-02-26 |
JPH02503919A (ja) | 1990-11-15 |
EP0359783A1 (fr) | 1990-03-28 |
EP0359783B2 (fr) | 2002-04-17 |
JP2512796B2 (ja) | 1996-07-03 |
EP0666080A1 (fr) | 1995-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK175666B1 (da) | Behandling af autoimmune sygdomme ved oral administration af autoantigener | |
CA2092905C (fr) | Traitement de maladies auto-immunes par l'administration orale d'autoantigenes | |
US5869054A (en) | Treatment of multiple sclerosis by oral administration of autoantigens | |
US5849298A (en) | Treatment of multiple sclerosis by oral administration of bovine myelin | |
US20050208061A1 (en) | Treatment of autoimmune diseases by oral administration of autoantigens | |
Kim et al. | Enhanced T cell proliferative response to type II collagen and synthetic peptide CII (255–274) in patients with rheumatoid arthritis | |
TW496872B (en) | Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes | |
EP0482089B1 (fr) | Procede de traitement de l'uveoretinite autoimmune chez l'homme | |
Birnbaum et al. | Heat shock proteins and experimental autoimmune encephalomyelitis (EAE): I. Immunization with a peptide of the myelin protein 2′, 3′ cyclic nucleotide 3′ phosphodiesterase that is cross‐reactive with a heat shock protein alters the course of EAE | |
Akuffo et al. | Differential recognition of Leishmania aethiopica antigens by lymphocytes from patients with local and diffuse cutaneous leishmaniasis. Evidence for antigen-induced immune suppression. | |
Elves | Immunology of cartilage | |
CN108452301A (zh) | 抗淋巴/胸腺细胞球蛋白在制备治疗神经自身免疫性疾病药物中的应用 | |
Singh et al. | Suppression of Experimental Autoimmune Uveitis in Lewis Rats by Oral Administration of RecombinantEscherichia coliExpressing Retinal S-Antigen | |
Gentner et al. | The relation between the cell-mediated immunological response and the induction of circulating antibodies to collagen in guinea-pigs. | |
JP2001029067A (ja) | 抗原特異的細胞傷害抑制性細胞の誘導方法 | |
JPH11509196A (ja) | 糖尿病の治療のためのヒト熱ショックタンパク質60由来の新規ペプチド、組成物、方法およびキット | |
MXPA98000191A (en) | Novedous peptides derived from human protein 60 produced by thermal shock, for the treatment of diabetes, compositions, methods and equi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUP | Patent expired |